Phaseline

Companies › Pierre Fabre Medicament

Pierre Fabre Medicament: clinical trials, targets and expected readouts

7 active drug programs in 35 registered trials: 24 Phase 2, 8 Phase 1, 3 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Binimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Melanoma; Non-Small Cell Lung Cancer; Solid Tumor, Adult; Solid Tumor …Dec 2026
Encorafenib
Serine/threonine-protein kinase B-raf inhibitor
BRAFPhase 3Melanoma; Non-Small Cell Lung CancerDec 2026
tabelecleucel
Allogeneic EBV-specific T-cell immunotherapy
–Phase 3Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD); Epstein-Barr Virus (EBV)-Associated DiseasesJun 2027
STX-241
Mutant-selective CNS-penetrant fourth generation EGFR tyrosine kinase inhibitor
EGFRPhase 1Non-small Cell Lung Cancer (NSCLC)Nov 2027
KIN-2787
BRAF inhibitor
BRAFPhase 1Solid Tumor, AdultNov 2028
STX-721/PFL-721
Exon 20 insertion-selective tyrosine kinase inhibitor
EGFR, HER2Phase 1Non-Small Cell Lung CancerDec 2029
VERT-002
MET inhibitor
METPhase 1Solid TumorOct 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT01991379BinimetinibPhase 1Gastrointestinal Stromal Tumor (GIST)OncologyNov 2026
NCT05195632EncorafenibPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT05195632BinimetinibPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT03839342BinimetinibPhase 2Solid TumorOncologyDec 2026
NCT03991819BinimetinibPhase 1Non-small Cell CarcinomaOncologyDec 2026
NCT03971409BinimetinibPhase 2Stage III Breast CancerOncologyJan 2027
NCT05026983BinimetinibPhase 2Clinical Stage IV Cutaneous Melanoma AJCC v8OncologyFeb 2027
NCT06159478BinimetinibPhase 2Low-grade GliomaOncologyFeb 2027
NCT05111561BinimetinibPhase 1Advanced Malignant Solid NeoplasmOncologyMar 2027
NCT04526782BinimetinibPhase 2Non Small Cell Lung CancerOncologyMar 2027
NCT04074096BinimetinibPhase 2Malignant MelanomaOncologyMar 2027
NCT05270044EncorafenibPhase 3MelanomaOncologyMar 2027
NCT05270044BinimetinibPhase 3MelanomaOncologyMar 2027
NCT04439344BinimetinibPhase 2Advanced LymphomaOncologyMar 2027
NCT05286788BinimetinibPhase 2Adamantinous CraniopharyngiomaOncologyApr 2027
NCT04554914tabelecleucelPhase 2Epstein-Barr Virus (EBV)-Associated DiseasesOncologyJun 2027
NCT04511013BinimetinibPhase 2Acral Lentiginous MelanomaOncologyJun 2027
NCT05564403BinimetinibPhase 2Advanced Biliary Tract CarcinomaOncologyOct 2027
NCT06567015STX-241Phase 1Non-small Cell Lung Cancer (NSCLC)OncologyNov 2027
NCT02910700BinimetinibPhase 2Metastatic Malignant Neoplasm in the BrainOncologyDec 2027
NCT04061980BinimetinibPhase 2BRAF NP_004324.2:p.V600MOncologyDec 2027
NCT02465060BinimetinibPhase 2Advanced LymphomaOncologyDec 2027
NCT06887088BinimetinibPhase 2Melanoma BRAF V600E/K MutatedOncologyJan 2028
NCT05170334BinimetinibPhase 2Metastatic Uveal MelanomaOncologyJan 2028
NCT04322383BinimetinibPhase 2Hairy Cell LeukemiaOncologyApr 2028
NCT05097378BinimetinibPhase 2MelanomaOncologyMay 2028
NCT05554367BinimetinibPhase 2Exocrine Pancreas CarcinomaOncologyAug 2028
NCT04913285BinimetinibPhase 1Solid Tumor, AdultOncologyNov 2028
NCT04913285KIN-2787Phase 1Solid Tumor, AdultOncologyNov 2028
NCT06207656BinimetinibPhase 2Colorectal CancerOncologyApr 2029
NCT04324112BinimetinibPhase 2Hairy Cell LeukemiaOncologyJun 2029
NCT06043817STX-721/PFL-721Phase 1Non-Small Cell Lung CancerOncologyDec 2029
NCT03394365tabelecleucelPhase 3Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Infectious diseaseMay 2030
NCT05564377BinimetinibPhase 2Advanced Malignant Solid NeoplasmOncologyJul 2030
NCT06669117VERT-002Phase 1Solid TumorOncologyOct 2030

From the company's SEC filings

Complete response letters from FDA

Targets

BRAF (2) EGFR (2) MAP2K1 (1) MAP2K2 (1) MET (1) HER2 (1)

Companies with the same targets

AstraZeneca Roche Pfizer Novartis Chia Tai Tianqing Pharmaceutical Group Shanghai Henlius Biotech Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Betta Pharmaceuticals Haisco Pharmaceutical Group

Companies built like this

Jiangsu Alphamab Biopharmaceuticals Shanghai Kechow Pharma Avistone Biotechnology Nanjing Sanhome Pharmaceutical Hansoh BioMedical R&D Company

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.